Accelerated fractionation vs. conventional fractionation radiation therapy for glottic cancer of T1-2N0M0 Phase III study (JCOG0701)

Accelerated fractionation vs. conventional fractionation radiation therapy for glottic cancer of T1-2N0M0 Phase III study (JCOG0701) - Accelerated fractionation vs. conventional fractionation radiation therapy for glottic cancer of T1-2N0M0 Phase III study (JCOG0701)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000819

Enrollment

360

Registered

2007-09-05

Start date

2007-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T1-2N0M0 glottic cancer

Interventions

A: Conventional fractionation radiation therapy (2 Gy/fr

T1:66 Gy/33 fr, T2:70 Gy/35 fr) B: Accelerated fractionation radiation therapy (2.4 Gy/fr

T1: 60 Gy/25 fr, T2: 64.8 Gy/27 fr)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Primary tumor site is vocal cord. 2) Histologically proven squamous cell carcinoma. 3) Extent of primary tumor is evaluated as T1 or T2 without impaired cord morbidity. 4) Clinical N0/M0. 5) Planned radiation therapy fulfill limitation of overall treatment time. 6) Aged 20 to 80 years old. 7) Performance status of 0 or 1. 8) No prior surgery or radiation therapy against larynx. 9) No prior chemotherapy against any malignancies. 10) Sufficient organ functions. 11) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Active bacterial or fungous infection. 2) Simultaneous or metachronous (within 5 years) double cancers. 3) Women during pregnancy or breast-feeding. 4) Psychosis. 5) Systemic steroids medication. 6) History of collagen disease except for rheumatism. 7) Uncontrollable diabetes mellitus or administration of insulin. 8) Hemodialysis medication 9) Uncontrollable hypertension. 10) History of severe heart disease, heart failure, myocardial infarction within 6 months or attack of angina pectoris within 6 months.

Design outcomes

Primary

Measure	Time frame
3-year progression-free survival	—

Secondary

Measure	Time frame
overall survival, local progression-free survival, disease-free survival, survival with preserved voice function, complete response rate, proportion of treatment completion in specific term, adverse events	—

Countries

Japan

Contacts

Public ContactNaoto Shikama

JCOG0701 Coordinating Office Saku Central Hospital

JCOG_sir@ml.jcog.jp0267-82-3131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026